MX2010004389A - Formulaciones de vancomicina liposomales. - Google Patents

Formulaciones de vancomicina liposomales.

Info

Publication number
MX2010004389A
MX2010004389A MX2010004389A MX2010004389A MX2010004389A MX 2010004389 A MX2010004389 A MX 2010004389A MX 2010004389 A MX2010004389 A MX 2010004389A MX 2010004389 A MX2010004389 A MX 2010004389A MX 2010004389 A MX2010004389 A MX 2010004389A
Authority
MX
Mexico
Prior art keywords
liposomal vancomycin
vancomycin formulations
liposomal
present disclosure
compositions
Prior art date
Application number
MX2010004389A
Other languages
English (en)
Inventor
Xingong Li
Walter R Perkins
Original Assignee
Transave Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transave Inc filed Critical Transave Inc
Publication of MX2010004389A publication Critical patent/MX2010004389A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere en parte a composiciones de vancomicina liposomales que tienen bajas relaciones de lípidos a fármacos y alta concentración de vancomicina. La presente descripción también se refiere en parte a métodos para formar dichas composiciones.
MX2010004389A 2007-10-23 2008-10-23 Formulaciones de vancomicina liposomales. MX2010004389A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98199007P 2007-10-23 2007-10-23
US10372508P 2008-10-08 2008-10-08
PCT/US2008/080954 WO2009055568A2 (en) 2007-10-23 2008-10-23 Liposomal vancomycin formulations

Publications (1)

Publication Number Publication Date
MX2010004389A true MX2010004389A (es) 2010-05-20

Family

ID=40563728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004389A MX2010004389A (es) 2007-10-23 2008-10-23 Formulaciones de vancomicina liposomales.

Country Status (8)

Country Link
US (2) US20090104257A1 (es)
EP (1) EP2214645A4 (es)
JP (3) JP5855829B2 (es)
CN (2) CN101917972A (es)
AU (2) AU2008316841B2 (es)
CA (1) CA2703179C (es)
MX (1) MX2010004389A (es)
WO (2) WO2009055571A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8226975B2 (en) 2005-12-08 2012-07-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
JP6184319B2 (ja) * 2010-05-20 2017-08-23 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド類およびケトライド類ならびにその中間体を調製するための工程
CA2803317A1 (en) * 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
WO2012020790A1 (ja) * 2010-08-11 2012-02-16 学校法人慶應義塾 感染症治療薬
MX354575B (es) * 2010-10-22 2018-03-12 Dr Reddys Laboratories Inc Uso de depósito de fosfolípidos viscosos estables en almacenamiento para tratar heridas..
WO2012149116A2 (en) * 2011-04-26 2012-11-01 Cedars-Sinai Medical Center Liposomal vancomycin for the treatment of mrsa infections
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
JP5932993B2 (ja) * 2011-06-17 2016-06-08 バーグ エルエルシー 吸入可能な医薬組成物
MX2015006681A (es) * 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
SI3466432T1 (sl) 2014-05-15 2020-11-30 Insmed Incorporated Postopek zdravljenja pljučnih netuberkuloznih mikobakterijskih okužb
WO2017083403A1 (en) * 2015-11-10 2017-05-18 Children's Research Institute, Children's National Medical Center Echinomycin formulation, method of making and method of use thereof
EP3906917A1 (en) * 2016-01-15 2021-11-10 SciDose Pharma LLC Formulations of vancomycin
EP3630154A4 (en) * 2017-05-22 2021-03-10 Insmed Incorporated LIPO-GLYCOPEPTIDE Cleavable Derivatives and Uses Thereof
US20200368313A1 (en) * 2017-12-29 2020-11-26 Wayne State University Drug delivery systems for treatment of infections
JP7460534B2 (ja) 2018-03-30 2024-04-02 インスメッド インコーポレイテッド リポソーム医薬品の連続製造方法
CN109078001B (zh) * 2018-09-21 2021-05-07 深圳浦瑞健康科技有限公司 一种万古霉素纳米脂质体组合物及其制备方法
US20220296515A1 (en) * 2019-05-28 2022-09-22 Nevakar Injectables Inc. Vancomycin Liposome Compositions and Methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203504A (es) * 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
JPH06345663A (ja) * 1993-06-08 1994-12-20 Sumitomo Pharmaceut Co Ltd バンコマイシン含有リポソーム製剤
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
EP3427742B1 (en) * 2002-10-29 2020-08-12 Insmed Incorporated Liposomes comprising an aminoglycoside for the treatment of pulmonary infections
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
AU2003295954A1 (en) * 2002-11-26 2004-06-18 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
US20070105758A1 (en) * 2005-10-31 2007-05-10 May Thomas B Vancomycin formulations having reduced amount of histamine

Also Published As

Publication number Publication date
US20090105126A1 (en) 2009-04-23
CA2703179A1 (en) 2009-04-30
JP2016130262A (ja) 2016-07-21
JP2011500836A (ja) 2011-01-06
AU2014202745A1 (en) 2014-06-12
US20090104257A1 (en) 2009-04-23
CN101917972A (zh) 2010-12-15
EP2214645A4 (en) 2013-09-25
AU2008316841A1 (en) 2009-04-30
EP2214645A2 (en) 2010-08-11
JP2014098032A (ja) 2014-05-29
CN103860469A (zh) 2014-06-18
JP5855829B2 (ja) 2016-02-09
CA2703179C (en) 2016-06-07
AU2008316841B2 (en) 2014-04-17
AU2014202745B2 (en) 2016-11-24
WO2009055568A2 (en) 2009-04-30
WO2009055568A3 (en) 2009-09-24
WO2009055571A2 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
MX2010004389A (es) Formulaciones de vancomicina liposomales.
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
EP4241767A3 (en) Novel lipids and compositions for the delivery of therapeutics
WO2009099719A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
CA2818187C (en) Bromodomain inhibitors and uses thereof
PH12015501193A1 (en) Boronate ester compounds and pharmaceutical compositions thereof
GEP20156253B (en) Lyophilized therapeutic peptibody formulations
WO2009149418A3 (en) Compositions for the in vivo delivery of rnai agents
MY161991A (en) Proteasome inhibitors
MX2022013691A (es) Formulaciones que contienen lipidos.
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
UA105503C2 (uk) Похідні 1-аміно-2-циклобутилетилборонової кислоти
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EP2320740A4 (en) PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS THEREOF
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
WO2009130616A3 (en) Improved tlr3 agonist compositions
WO2007105015A3 (en) DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
WO2008016730A3 (en) Compositions and methods for reducing cellular fat
PH12014500714A1 (en) Stable sns-595 compositions and methods of preparation
MXPA05008902A (es) Soluciones de drogas en mentol.
WO2010025011A8 (en) Formulations of canfosfamide and their preparation
GEP20125563B (en) 2-amino-2-phenylalkanol derivatives, preparation method thereof and pharmaceutical compositions containing same

Legal Events

Date Code Title Description
FG Grant or registration